Goodpasture syndrome surgery

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Ali Poyan Mehr, M.D. [2]; Associate Editor(s)-in-Chief: Krzysztof Wierzbicki M.D. [3] Akshun Kalia M.B.B.S.[4]

Overview

Surgery is not the first-line treatment option for patients with Goodpasture syndrome. Renal transplantation is usually reserved for patients who present with undetectable circulating anti-glomerular basement antibodies in serum for 12 months and atleast 6 months after stopping the use of cytotoxic agents.

Surgery

Surgical intervention in the form of renal transplantation is indicated in patients with end-stage renal disease.
Renal transplantation may be performed when anti-glomerular basement membranes are undetectable for 6 months with no signs of pulmonary involvement.^[1]^[2]^[3]

References

↑ Menn-Josephy H, Beck LH (2015). “Recurrent glomerular disease in the kidney allograft”. Front Biosci (Elite Ed). 7: 135–48. PMID 25553369.
↑ “Notice”. Kidney Int Suppl (2011). 2 (2): 139. 2012. doi:10.1038/kisup.2012.9. PMC 4089568. PMID 25028634.
↑ Chen M, Kallenberg CG (2010). “ANCA-associated vasculitides–advances in pathogenesis and treatment”. Nat Rev Rheumatol. 6 (11): 653–64. doi:10.1038/nrrheum.2010.158. PMID 20924413.

Template:WH Template:WS

[pmid25553369-1] Menn-Josephy H, Beck LH (2015). “Recurrent glomerular disease in the kidney allograft”. Front Biosci (Elite Ed). 7: 135–48. PMID 25553369.

[pmid25028634-2] “Notice”. Kidney Int Suppl (2011). 2 (2): 139. 2012. doi:10.1038/kisup.2012.9. PMC 4089568. PMID 25028634.

[pmid20924413-3] Chen M, Kallenberg CG (2010). “ANCA-associated vasculitides–advances in pathogenesis and treatment”. Nat Rev Rheumatol. 6 (11): 653–64. doi:10.1038/nrrheum.2010.158. PMID 20924413.

[1]

[2]

[3]

Goodpasture syndrome surgery

Overview

Surgery

References

Looking for the patient version?